Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients,

Simona Soverini, Caterina De Benedittis, Alessandra Gnani, Ilaria Iacobucci, PhD, Domenico Russo, Federica Cattina, MD, Fausto Castagnetti, Gabriele Gugliotta, Cristina Papayannidis, Antonella Vitale, Loredana Elia, Robin Foà, Francesca Palandri, Annalisa Lonetti, Maria Teresa Bochicchio, Sandra Durante, Gianantonio Rosti, MD, Michele Baccarani, MD, Giovanni Martinelli

Blood (2011) 118 (21): 3775.

https://doi.org/10.1182/blood.V118.21.3775.3775

Published: 2011

Journal Articles

Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2 nd -Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement

Blood (2011) 118 (21): 575.

https://doi.org/10.1182/blood.V118.21.575.575

Published: 2011

Journal Articles

Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies

Blood (2011) 118 (21): 112.

https://doi.org/10.1182/blood.V118.21.112.112

Published: 2011

Journal Articles

Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party

Blood (2010) 116 (21): 2279.

https://doi.org/10.1182/blood.V116.21.2279.2279

Published: 2010

Journal Articles

Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression

Simona Soverini, Angela Poerio, Alberto Ferrarini, Ilaria Iacobucci, Marco Sazzini, Joannah Score, PhD, Enrico Giacomelli, Luciano Xumerle, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Francesca Palandri, Gabriele Gugliotta, Marilina Amabile, Gianantonio Rosti, Michele Baccarani, Nicholas C. P. Cross, MD, Massimo Delledonne, Giovanni Martinelli

Blood (2010) 116 (21): 885.

https://doi.org/10.1182/blood.V116.21.885.885

Published: 2010

Journal Articles

Low-Level Bcr-Abl Kinase Domain Mutations Are Very Rare In Chronic Myeloid Leukemia Patients Who Are In Major Molecular Response After 12 Months of First-Line Nilotinib Therapy.

Simona Soverini, PhD, Angela Poerio, Caterina Debenedittis, Ilaria Iacobucci, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Francesca Palandri, Gabriele Gugliotta, Marilina Amabile, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli, MD

Blood (2010) 116 (21): 1666.

https://doi.org/10.1182/blood.V116.21.1666.1666

Published: 2010

Journal Articles

Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience.

Blood (2009) 114 (22): 2027.

https://doi.org/10.1182/blood.V114.22.2027.2027

Published: 2009

Journal Articles

High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes.

Simona Soverini, PhD, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Annalisa Astolfi, Serena Formica, Francesca Palandri, Ilaria Iacobucci, Gabriele Gugliotta, Angela Poerio, Marilina Amabile, Giulia Marzocchi, Nicoletta Testoni, Elisabetta Abruzzese, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli

Blood (2009) 114 (22): 2176.

https://doi.org/10.1182/blood.V114.22.2176.2176

Published: 2009

Journal Articles

Whole-Transcriptome Sequencing of a Chronic Myeloid Leukemia (CML) Patient at Diagnosis and at the Time of Progression to Blast Crisis (BC).

Blood (2009) 114 (22): 4259.

https://doi.org/10.1182/blood.V114.22.4259.4259

Published: 2009

Journal Articles

High-Resolution Genome Wide Copy Number Alteration (CNA) and Loss of Heterozigosity (LOH) Analysis in Chronic Myeloid Leukemia (CML) Shows That High and Intermediate Sokal Risk Pts (Pts) Have Multiple Losses Targeting Genes Involved in DNA Repair.

Simona Soverini, PhD, Sabrina Colarossi, Alessandra Gnani, Annalisa Astolfi, Serena Formica, Fausto Castagnetti, Francesca Palandri, Gabriele Gugliotta, Angela Poerio, Ilaria Iacobucci, Marilina Amabile, Giulia Marzocchi, Simona Luatti, Carolina Terragna, Sandra Durante, Nicoletta Testoni, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli

Blood (2009) 114 (22): 3262.

https://doi.org/10.1182/blood.V114.22.3262.3262

Published: 2009

Journal Articles

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

Blood (2009) 114 (10): 2168–2171.

https://doi.org/10.1182/blood-2009-01-197186

Published: 2009

Includes: Supplemental data

Journal Articles

Different Isoforms of the B-Cell Mutator Activation-Induced Cytidine Deaminase (AID) Are Aberrantly Over-Expressed in BCR-ABL1 -Positive Acute Lymphoblastic Leukemia (ALL) Patients and Promote Genetic Instability.

Blood (2008) 112 (11): 1497.

https://doi.org/10.1182/blood.V112.11.1497.1497

Published: 2008

Journal Articles

Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.

Blood (2008) 112 (11): 2118.

https://doi.org/10.1182/blood.V112.11.2118.2118

Published: 2008

Journal Articles

Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Already Harbor Bcr-Abl Kinase Domain Mutations at Low Levels at the Time of Diagnosis - a Report by the GIMEMA ALL Working Party

Blood (2008) 112 (11): 722.

https://doi.org/10.1182/blood.V112.11.722.722

Published: 2008

Journal Articles

Multidrug Resistance Gene (MDR1) Polymorphisms May Serve as Predictors of Resistance to Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients.

Simona Soverini, Sabrina Angelini, Eleonora Turrini, Alessandra Gnani, Sabrina Colarossi, Giovanni Perini, Ilaria Iacobucci, Patrizia Hrelia, Giorgio Cantelli Forti, Daniela Cilloni, Giuseppe Saglio, Fabrizio Pane, Michele Baccarani, Thea Kalebic, Giovanni Martinelli

Blood (2007) 110 (11): 1946.

https://doi.org/10.1182/blood.V110.11.1946.1946

Published: 2007

Journal Articles

In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations.

Simona Soverini, Alessandra Gnani, Sabrina Colarossi, Fausto Castagnetti, Elisabetta Abruzzese, Serena Merante, Massimo Breccia, Adele Capucci, Giorgina Specchia, Franca Radaelli, Francesca Palandri, Angela Poerio, Ilaria Iacobucci, Marilina Amabile, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli

Blood (2007) 110 (11): 1934.

https://doi.org/10.1182/blood.V110.11.1934.1934

Published: 2007

Journal Articles

Philadelphia Chromosome-Positive Leukemia Patients Who Harbor Imatinib-Resistant Mutations Have a Higher Likelihood of Developing Additional Mutations Associated with Resistance to Novel Tyrosine Kinase Inhibitors.

Simona Soverini, Alessandra Gnani, Sabrina Colarossi, Fausto Castagnetti, Francesca Palandri, Panagiota Giannoulia, Stefania Paolini, Elisabetta Abruzzese, Serena Merante, Michela Rondoni, Ilaria Iacobucci, Angela Poerio, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli

Blood (2007) 110 (11): 322.

https://doi.org/10.1182/blood.V110.11.322.322

Published: 2007

Journal Articles

Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts).

Simona Soverini, Giovanni Martinelli, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Gianantonio Rosti, Costanza Bosi, Stefania Paolini, Michela Rondoni, Pier Paolo Piccaluga, Francesca Palandri, Panagiota Giannoulia, Giulia Marzocchi, Simona Luatti, Elisabetta Abruzzese, Ilaria Iacobucci, Nicoletta Testoni, Michele Baccarani

Blood (2006) 108 (11): 836.

https://doi.org/10.1182/blood.V108.11.836.836

Published: 2006

Journal Articles

A Novel Denaturing-High Performance Liquid Chromatography (D-HPLC)-Based Method for Kit Mutation Screening of Patients (pts) with Systemic Mastocytosis (SM) Allows the Identification of Unreported Kit Variants.

Sabrina Colarossi, Simona Soverini, Alessandra Gnani, Michela Rondoni, Simona Gatto, Serena Merante, Enrico Gottardi, Daniela Cilloni, Pellegrino Musto, Mario Tiribelli, Roberta Zanotti, Giovanni Martinelli, Michele Baccarani

Blood (2006) 108 (11): 4849.

https://doi.org/10.1182/blood.V108.11.4849.4849

Published: 2006

Journal Articles

A Study of the Binding Mode and the In Vitro Activity of the Protein Tyrosine Kinase Inhibitor SKI-606 in the BCR-ABL Positive Cells.

Tiziana Grafone, Simona Soverini, Gianluca Tasco, Manuela Mancini, Frank Boschelli, Jennifer Golas, David Frauling, Sabrina Colarossi, Emanuela Ottaviani, Alessandra Gnani, Giannoulia Panagiota, Fausto Castagnetti, Rita Casadio, Gianantonio Rosti, Giovanni Martinelli, Michele Baccarani

Blood (2006) 108 (11): 2335.

https://doi.org/10.1182/blood.V108.11.2335.2335

Published: 2006

NARROW

Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients,

Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2 nd -Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement

Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies

Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party

Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression

Low-Level Bcr-Abl Kinase Domain Mutations Are Very Rare In Chronic Myeloid Leukemia Patients Who Are In Major Molecular Response After 12 Months of First-Line Nilotinib Therapy.

Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience.

High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes.

Whole-Transcriptome Sequencing of a Chronic Myeloid Leukemia (CML) Patient at Diagnosis and at the Time of Progression to Blast Crisis (BC).

High-Resolution Genome Wide Copy Number Alteration (CNA) and Loss of Heterozigosity (LOH) Analysis in Chronic Myeloid Leukemia (CML) Shows That High and Intermediate Sokal Risk Pts (Pts) Have Multiple Losses Targeting Genes Involved in DNA Repair.

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

Different Isoforms of the B-Cell Mutator Activation-Induced Cytidine Deaminase (AID) Are Aberrantly Over-Expressed in BCR-ABL1 -Positive Acute Lymphoblastic Leukemia (ALL) Patients and Promote Genetic Instability.

Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.

Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Already Harbor Bcr-Abl Kinase Domain Mutations at Low Levels at the Time of Diagnosis - a Report by the GIMEMA ALL Working Party

Multidrug Resistance Gene (MDR1) Polymorphisms May Serve as Predictors of Resistance to Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients.

In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations.

Philadelphia Chromosome-Positive Leukemia Patients Who Harbor Imatinib-Resistant Mutations Have a Higher Likelihood of Developing Additional Mutations Associated with Resistance to Novel Tyrosine Kinase Inhibitors.

Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts).

A Novel Denaturing-High Performance Liquid Chromatography (D-HPLC)-Based Method for Kit Mutation Screening of Patients (pts) with Systemic Mastocytosis (SM) Allows the Identification of Unreported Kit Variants.

A Study of the Binding Mode and the In Vitro Activity of the Protein Tyrosine Kinase Inhibitor SKI-606 in the BCR-ABL Positive Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only